These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

898 related articles for article (PubMed ID: 36713414)

  • 81. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Current Status of CAR T Cell Therapy for Leukemias.
    Harris K; LaBelle JL; Bishop MR
    Curr Treat Options Oncol; 2021 Jun; 22(7):62. PubMed ID: 34097135
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy.
    Yagi Y; Kanemasa Y; Sasaki Y; Goto S; Yamamura Y; Masuda Y; Fujita K; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Matsuda S; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Shimoyama T
    J Clin Exp Hematop; 2024; 64(2):107-118. PubMed ID: 38925972
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.
    Zhang C; He J; Liu L; Wang J; Wang S; Liu L; Ge J; Gao L; Gao L; Kong P; Liu Y; Liu J; Han Y; Zhang Y; Sun Z; Ye X; Yin W; Sersch M; Shen L; Cao WW; Zhang X
    Blood Cancer J; 2022 Jun; 12(6):96. PubMed ID: 35750687
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
    Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice.
    Zhao K; Ren C; Tang D; Zhao L; Chen X; Wang Y; Xu K
    Front Immunol; 2023; 14():1101769. PubMed ID: 36761733
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
    Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
    Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
    [TBL] [Abstract][Full Text] [Related]  

  • 88. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
    Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
    Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
    Li Z; Meng F; Li J; Wu T
    Front Immunol; 2022; 13():931452. PubMed ID: 35903089
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy.
    Xiao X; Chen P; Zhong Y; Luo X; Liu Y; Lu Y; Jin X; Qian W; Han W; Liang A; Liu H
    Cancer Med; 2023 Nov; 12(22):20838-20846. PubMed ID: 37962082
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion.
    Liang Z; Xu H; Zhou X; Yang J; Tu S; He Y; Zhou L; Li Y
    Hum Cell; 2023 Sep; 36(5):1716-1728. PubMed ID: 37418233
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Efficacy and side effects of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory gastrointestinal lymphoma.
    Jiang YL; Mu J; Cui R; Li X; Wang J; Li Q; Li J; Mou N; Deng Q
    Cancer Med; 2024 Feb; 13(4):e7064. PubMed ID: 38457256
    [TBL] [Abstract][Full Text] [Related]  

  • 93. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
    Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
    Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies.
    Pu LF; Zheng HM; Feng XJ; Charwudzi A; Liang X; Hu LH; Ding YY; Liu ZL; Liao Y; Xiong SD
    J Transl Med; 2024 Jul; 22(1):613. PubMed ID: 38956649
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R CD20-negative transformed follicular lymphoma with
    Zhang J; Cai D; Gao R; Miao Y; Cui Y; Liu Z; Zhang H; Yan X; Su N
    Front Immunol; 2023; 14():1307242. PubMed ID: 38143763
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma.
    Chen X; Li X; Liu Y; Zhang Z; Zhang X; Huang J; Li H; Li F; Zhang L; Li L; Wu X; Ma W; Sun Z; Yu H; Zhou Z; Feng X; Cui K; Li Z; Zhang H; Zeng Y; Wan X; Chen YH; Zhang M; Zhang Y
    Immunotherapy; 2020 Jul; 12(10):681-696. PubMed ID: 32580597
    [No Abstract]   [Full Text] [Related]  

  • 99. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
    Read JA; Rouce RH; Mo F; Mamonkin M; King KY
    Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
    Medina I; Carpio C; Ruiz-Camps I; Albasanz-Puig A; Lopez-Godino O; Esperalba J; Beas F; Sanchez-Salinas M; Iacoboni G; Barba P
    Immunotherapy; 2023 Nov; 15(16):1369-1374. PubMed ID: 37718888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.